Abstract

ObjectiveTo assess clinical significance of CD147 in renal cell carcinoma.MethodsCollect case-control studies which focus on CD147's expression in renal cell carcinoma. Trails were retrieved from CBM, CNKI, Wan-fang database, PubMed, Cochrane Library and Embase. According to the inclusion and exclusion criteria, data extraction and quality assessment were done by two researchers independently, and outcomes were pooled with Revman5.3 and STATA14.0.ResultsA total of 11 studies were confirmed, among which renal cell carcinoma 887 cases, non-cancer 505cases. As for the positive rate of CD147, there are statistical differences among survival, renal cell carcinoma tissue vs. non-cancer tissues [OR= 8.19, P= 0.0002], with vs. without lymph node metastases [OR= 6.52, P= 0.001], clinical stage III~IV vs. II~I [OR= 4.07, P< 0.00001], histopathological stage III~IV vs. II [OR= 3.01, P= 0.002], histopathological stage III~IV vs. I [OR= 7.50, P< 0.00001], tumor size [OR= 5.01, P= 0.0007]. No significant difference was tested among different age, gender, histological types and Position of cancer.ConclusionAs shown in our results, CD 147 may participate the whole course of carcinogenesis of renal cell carcinoma, which might be valuable for the diagnosis, treatment and prognosis.

Highlights

  • Renal cell carcinoma (RCC) is the most common malignancy of kidneys found in adults [1]

  • We investigated the relationship between CD147 expression 1,3,5,10- and 15-survival

  • We combined the data with fixed model effect (I2=0, P=0.728), and found that CD147 positive expression bring a worse 5-year survival comparing with negative patients (HR=1.61, 95%CI= 1.04-2.49) (Figure 2)

Read more

Summary

Introduction

Renal cell carcinoma (RCC) is the most common malignancy of kidneys found in adults [1]. A number of biomarkers such as survivin, MCT1, MCT4, Cullin 1 and CD147 have been found to be involved in its development and progression according to some reports [6,7,8]. Among these markers, extracellular matrix metalloproteinase inducer (EMMPRIN, known as CD147 or basigin) is highly expressed in a variety of tumors, facilitating tumor invasion and metastasis [9]. The same conflict is seen in the studies of metastasis status and TNM stage [16, 18,19,20]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.